SG11202011969WA - Methods for characterizing protein complexes - Google Patents

Methods for characterizing protein complexes

Info

Publication number
SG11202011969WA
SG11202011969WA SG11202011969WA SG11202011969WA SG11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA SG 11202011969W A SG11202011969W A SG 11202011969WA
Authority
SG
Singapore
Prior art keywords
methods
protein complexes
characterizing protein
characterizing
complexes
Prior art date
Application number
SG11202011969WA
Other languages
English (en)
Inventor
Nina Liu
Michael Rosconi
Erica Pyles
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202011969WA publication Critical patent/SG11202011969WA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G01N21/49—Scattering, i.e. diffuse reflection within a body or fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/0005—Field flow fractionation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
SG11202011969WA 2018-08-30 2019-08-28 Methods for characterizing protein complexes SG11202011969WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862724700P 2018-08-30 2018-08-30
PCT/US2019/048526 WO2020047067A1 (en) 2018-08-30 2019-08-28 Methods for characterizing protein complexes

Publications (1)

Publication Number Publication Date
SG11202011969WA true SG11202011969WA (en) 2020-12-30

Family

ID=68063024

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011969WA SG11202011969WA (en) 2018-08-30 2019-08-28 Methods for characterizing protein complexes

Country Status (15)

Country Link
US (2) US11754569B2 (ko)
EP (1) EP3775926A1 (ko)
JP (1) JP2021535361A (ko)
KR (1) KR20210053816A (ko)
CN (1) CN112601963A (ko)
AU (1) AU2019333047A1 (ko)
BR (1) BR112020026348A2 (ko)
CA (1) CA3100038A1 (ko)
EA (1) EA202190032A1 (ko)
IL (1) IL280884A (ko)
MX (1) MX2021002281A (ko)
SG (1) SG11202011969WA (ko)
TW (1) TW202024639A (ko)
WO (1) WO2020047067A1 (ko)
ZA (1) ZA202007067B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210040197A1 (en) 2019-08-08 2021-02-11 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
TW202334223A (zh) 2021-11-11 2023-09-01 美商再生元醫藥公司 Ｃｄ２０－ｐｄ１結合分子及其使用方法
CN114874349B (zh) * 2022-06-15 2023-03-10 河北大学 一种基于场流分离技术分离纯化灵芝多糖的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
KR100562195B1 (ko) 2002-03-08 2006-03-20 에이에스엠엘 네델란즈 비.브이. 리소그래피용 마스크, 마스크 제조방법, 리소그래피장치및 디바이스제조방법
RS52643B (en) 2006-06-02 2013-06-28 Regeneron Pharmaceuticals Inc. HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DK2178916T3 (en) 2007-07-31 2015-01-12 Regeneron Pharma Human antibodies to human cd20 and method thereof for use
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PL2975051T3 (pl) 2009-06-26 2021-09-20 Regeneron Pharmaceuticals, Inc. Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CA2794631A1 (en) 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
KR101867279B1 (ko) 2010-10-06 2018-06-15 리제너론 파아마슈티컬스, 인크. 항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
WO2013074557A1 (en) 2011-11-14 2013-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
MX357393B (es) 2012-01-23 2018-07-06 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti - ang2.
US10481164B2 (en) * 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
EP2839290B1 (de) 2012-04-17 2019-03-06 Aeneas GmbH & Co. KG Verfahren zur präsymptomatischen diagnostik von zöliakie und glutensensitivität
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
NZ704771A (en) 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
WO2014152195A1 (en) 2013-03-15 2014-09-25 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
HUE045307T2 (hu) 2014-03-11 2019-12-30 Regeneron Pharma EGFRVIII-ellenes antitestek és alkalmazásaik
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US9795121B2 (en) 2014-05-05 2017-10-24 Regeneron Pharmaceuticals, Inc. Humanized C3 animals
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
MX2017003535A (es) 2014-09-16 2017-10-27 Regeneron Pharma Anticuerpos anti-glucagon y sus usos.
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
RU2018130525A (ru) 2016-01-27 2020-02-27 Цсл Беринг Ленгнау Аг РЕКОМБИНАНТНЫЕ Fc-МУЛЬТИМЕРЫ IgG
JP2021506241A (ja) * 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用

Also Published As

Publication number Publication date
ZA202007067B (en) 2024-04-24
CA3100038A1 (en) 2020-03-05
KR20210053816A (ko) 2021-05-12
WO2020047067A1 (en) 2020-03-05
US20200072844A1 (en) 2020-03-05
US11754569B2 (en) 2023-09-12
AU2019333047A1 (en) 2020-12-03
US20240019443A1 (en) 2024-01-18
BR112020026348A2 (pt) 2021-03-30
CN112601963A (zh) 2021-04-02
EP3775926A1 (en) 2021-02-17
JP2021535361A (ja) 2021-12-16
TW202024639A (zh) 2020-07-01
EA202190032A1 (ru) 2021-03-12
MX2021002281A (es) 2021-05-27
IL280884A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
IL281804A (en) Protein purification methods
IL288613A (en) Multispecific proteins
IL280884A (en) Methods for characterizing protein complexes
DK3737402T3 (en) Modificeret protein
IL263342A (en) A method for stabilizing proteins
EP3463414C0 (en) PROTEIN INTERFACES
IL279355A (en) Antigen binding protein against STEAP1
IL281088A (en) FLT3L - based chimeric proteins
GB201803724D0 (en) Methods
SG11202109901TA (en) Protein binders for irhom2
IL292145A (en) Methods for protein characterization in host cells
IL284317A (en) FAB pseudoproteins are multispecific binding proteins
IL258340A (en) Quantifying met protein for cancer treatment
GB201802486D0 (en) Methods
GB201708330D0 (en) Fusion protein for enhancing intestinal regeneration
GB201815670D0 (en) Protein editing
ZA201901862B (en) Modified factor h binding protein
SG11202007342QA (en) Methods
GB201805466D0 (en) Methods
GB2558968B (en) G Proteins
EP3784679C0 (en) PHOSPHINIMINE AMIDO-ETHER COMPLEXES
GB201814451D0 (en) Methods
GB201703416D0 (en) Method for protein expression
GB201703049D0 (en) Single-strand binding protein
GB201614627D0 (en) Antigen binding proteins